Paris—Dentons Paris advised Bpifrance Large Venture on the Series A funding of Aqemia.

Aqemia is a Paris-based deeptech founded in 2019 and specialised in drug discovery by combining quantum physics and artificial intelligence.

The €30 million Series A funding round was co-led by Eurazeo and Bpifrance, through its Large Venture fund, with the participation of Elaia, its historic investor.

This financing will further support Aqemia's core mission: to massively advance drug discovery through a first-class technology platform combining quantum-inspired physics and artificial intelligence.

Our multidisciplinary Paris team included:

• On corporate and contractual aspects: Olivia Guéguen (partner), Laura Godard, Pierre-Marie Gallo, Nouçayba Soltani and Marie Tavernier (associates)
• Employment law: Katell Déniel-Allioux (partner) and Julie Ragueneau (counsel)
• Intellectual property: Loïc Lemercier (partner) and Tom Blanchet (associate)

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com